Effects of Sustained-release Oral Sodium Nitrite on Postoperative Pain and Recovery Following Total Knee Arthroplasty

NCT ID: NCT05893160

Last Updated: 2025-06-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2026-06-01

Study Completion Date

2028-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will determine whether a drug called sodium nitrite helps improve pain and post-operative recovery associated with knee replacement surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The goal of this study is to examine the potential for oral sodium nitrite supplementation to reduce postoperative pain and inflammation and improve functional recovery in individuals undergoing unilateral revision total knee replacement. A sustained release formulation of sodium nitrite (40 mg) administered twice daily will be compared with placebo for a 30-day treatment period. Primary objectives are to evaluate pain and markers of functional improvement.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental Intervention

The intervention group will receive sodium nitrite SR (40 mg b.i.d. for 30 days)

Group Type EXPERIMENTAL

JAN101 SR

Intervention Type DRUG

The dosage form of JAN101 to be used in clinical investigations is a sustained release (SR) tablet containing Sodium Nitrite drug substance.

Placebo

The comparison group will receive an inert placebo on the same schedule as the intervention group

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Inert placebo formulation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

JAN101 SR

The dosage form of JAN101 to be used in clinical investigations is a sustained release (SR) tablet containing Sodium Nitrite drug substance.

Intervention Type DRUG

Placebo

Inert placebo formulation

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sodium Nitrite SR

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female individuals aged 18-70
* Ambulatory with knee pain for greater than 6 months prior to surgery, and willing and able to comply with all study requirements will be considered eligible.

Exclusion Criteria

* Severe hypertension (systolic blood pressure greater than or equal to 200 mmHg or diastolic blood pressure greater than or equal to 120 mmHg);
* BMI greater than 45 kg/m2;
* Active smoker or stopped smoking within 6 months of enrollment;
* Active local or systemic malignancy, such as lung cancer or leukemia;
* Cardiovascular disease resulting in dyspnea at rest;
* Peripheral neurovascular disease;
* Anemia;
* Hematological disease (eg, coagulopathy, sickle cell disease/anemia);
* Hemoglobin variant;
* Glucose-6-phosphate dehydrogenase deficiency;
* Methemoglobin reductase deficiency;
* Known sensitivity to nitrites;
* Liver disease;
* Use of phosphodiesterase type 5 inhibitors;
* Use of sildenafil (Viagra);
* Systemic treatment with antibiotics, immunosuppressants including corticosteroids, medications for migraine, allopurinol, tricyclic antidepressants, antihistamines, and/or nitrates currently or in the last month;
* Use of nitrovasodilators (e.g. GTN) within the last month;
* Use of protein pump inhibitors within the last month;
* History of substance abuse;
* Recent surgery or hospitalization (within last 6 months);
* Inability to swallow a pill;
* Failure to provide full consent;
* Involvement with a worker's compensation, personal injury, or other legal matter related to participant health.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Alabama at Birmingham

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jennifer DeBerry

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jennifer DeBerry, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Alabama at Birmingham

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UAB

Identifier Type: OTHER

Identifier Source: secondary_id

IRB-300010657

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Acute Pain and Inflammation After Surgery
NCT00774540 COMPLETED PHASE4